Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate Update
SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ: CBIO)…
News
VBL Therapeutics to Host In-Person Key Opinion Leader Seminar on Ovarian Cancer
Three leading experts in gynecological oncology will discuss treatment landscape and unmet needs in ovarian…
Longeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer’s Disease in Alzheimer’s & Dementia®: The Journal of the Alzheimer’s Association
Results Support Further Exploration of Therapeutic Potential of Lomecel-B to Slow Cognitive Decline, Improve Quality…
Portage Biotech Provides Update on Clinical-Stage and Development Programs
Preliminary safety data suggests lead iNKT agonists, PORT-2 and PORT-3, are well tolerated supporting continued…
Science 37® Adds Acclaimed Researcher and Oncologist, Dr. Shaalan Beg to Bolster Therapeutic Depth
Addition of Dr. Beg provides Science 37 with expertise to apply more decentralized clinical trial…
Rapid Therapeutic Science Laboratories Announces 1-for-25 Reverse Stock Split
DALLAS, Texas, March 31, 2022 (GLOBE NEWSWIRE) — Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)…
Aptose to Present at Canaccord Genuity’s 2022 Horizons in Oncology Virtual Conference
SAN DIEGO and TORONTO, March 31, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or…
Incyclix Bio Announces $30 Million Series B Financing Led by Boxer Capital
Funds to support clinical development of INX-315, the company’s lead Cyclin-Dependent Kinase 2 inhibitor Sid…
Acerus Announces Amendments to Loan Facility
TORONTO, March 31, 2022 (GLOBE NEWSWIRE) — Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP;…
Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study
CAMBRIDGE, Mass., March 31, 2022 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology…
Agile Therapeutics® Announces First Twirla® Commercial Targeting Gen Z
Partners with Award-Winning Director Maya Albanese “Patch and Play” introduces the features of the Twirla…
Abeona Therapeutics Announces Strategy Update and 2021 Financial Results
EB-101 pivotal phase 3 VIITAL™ study in RDEB achieves target enrollment; top-line data expected in…
Auxly Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Outlook for 2022
TORONTO, March 31, 2022 (GLOBE NEWSWIRE) — Auxly Cannabis Group Inc. (TSX ‐ XLY) (OTCQX:…
InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients
Vilobelimab treatment results in relative reduction in 28-day all-cause mortality of 23.9% compared to placebo…
Windtree Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology…
Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare Fund, an affiliate of CBC Group
CHESTERBROOK, Pa., March 31, 2022 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company…
ObsEva Annual Report 2021
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva,…
BioNTech Announces ADS Repurchase Program
MAINZ, Germany, March 31, 2022 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or the…
XORTX Files IND with US FDA
● Autosomal Dominant Polycystic Kidney Disease – XRx-008 Program IND Filed ● CALGARY, Alberta, March 31,…
Trevena Reports Fourth Quarter and Full Year 2021 Results
— OLINVYK® utilization gaining traction in key target markets Seasoned Biopharma Leader Patricia Drake appointed…